Markedly decreasing azithromycin susceptibility of < em > Neisseria gonorrhoeae < /em > , Germany, 2014 to 2021

Euro Surveill. 2021 Aug;26(31). doi: 10.2807/1560-7917.ES.2021.26.31.2100616.ABSTRACTWe monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.PMID:34355690 | DOI:10.2807/1560-7917.ES.2021.26.31.2100616
Source: Euro Surveill - Category: Infectious Diseases Authors: Source Type: research